EMEA-001657-PIP01-14-M01
Key facts
| Invented name |
Baqsimi
|
| Active substance |
Glucagon
|
| Therapeutic area |
Endocrinology, -gynacology-fertility-metabolism
|
| Decision number |
P/0301/2020
|
| PIP number |
EMEA-001657-PIP01-14-M01
|
| Pharmaceutical form(s) |
Nasal powder
|
| Condition(s) / indication(s) |
Treatment of hypoglycaemia
|
| Route(s) of administration |
Intranasal use
|
| Contact for public enquiries |
Eli Lilly & Company Limited
E-mail: eu_paediatric@lilly.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|